Tag Archives: yervoy

T-Cells Test May Predict Success of New Drug Combination for Mesothelioma

new drug combination for mesothelioma

A month after the FDA approved a new drug combination for pleural mesothelioma, scientists are discovering more about who might benefit the most from this treatment.  A new report in EBioMedicine suggests that the success of the new drug combination for mesothelioma depends on the presence and activation of special immune system cells. Researchers in the Netherlands found that patients with enough of the right kind of T-cells had the best results. The findings could help doctors screen out mesothelioma patients who are less likely to benefit.  The Long-Awaited New Drug Combination for Mesothelioma  The two medicines in the new drug combination for mesothelioma are nivolumab (Opdivo) and ipilimumab (Yervoy).  The FDA approved a mix of the two immunotherapy drugs … Continue reading T-Cells Test May Predict Success of New Drug Combination for Mesothelioma »

New Drug Combination for Mesothelioma Wins FDA Approval

New Drug Combination for Mesothelioma

The FDA has approved a new drug combination for mesothelioma. It is the first systemic treatment for mesothelioma to win FDA approval in 16 years.  The combination includes a pair of immunotherapy drugs that complement each other. Both drugs are immune checkpoint inhibitors. They are approved to treat people with inoperable pleural mesothelioma.  “Today’s approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival for patients with malignant pleural mesothelioma,” says Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence. New Treatment Options Needed Pleural mesothelioma is a virulent cancer of the membrane that surrounds the lungs. Asbestos exposure is usually the trigger. Many countries have banned asbestos. In the US, … Continue reading New Drug Combination for Mesothelioma Wins FDA Approval »

Non-Epithelioid Mesothelioma: Immunotherapy Combo Could be the New Standard of Care

Two immunotherapy drugs could become the new standard of care for people with non-epithelioid mesothelioma.  All forms of malignant mesothelioma are deadly. But people with a non-epithelioid mesothelioma subtype are less likely to respond to standard treatments. Their variety of mesothelioma is especially resistant to chemotherapy with cisplatin and Alimta. This has been the mainstay of pleural mesothelioma treatment since 2004. But a new trial shows two immunotherapy drugs extended mesothelioma survival better than chemotherapy. This could be especially good news for patients with non-epithelioid mesothelioma.  Checkpoint Inhibitors for Mesothelioma Most people with pleural mesothelioma start with chemotherapy. Chemotherapy can often extend life by a few months. It is most beneficial for patients with epithelioid mesothelioma. But this approach does … Continue reading Non-Epithelioid Mesothelioma: Immunotherapy Combo Could be the New Standard of Care »